Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Chronic Lymphoid Neoplasms Multiple Myeloma Multiple Myeloma:

Management of relapsed/refractory multiple myeloma and minimal residual disease assessment

CC-93269, a 2+1 BCMA TCE, shows a manageable safety profile and promising efficacy, including MRD-negative sCRs, in pts with heavily pretreated RRMM. The study continues to enroll in the dose-escalation phase. 
 
————————————————————————————————————————————————————————
 
 
Maria-Victoria Mateos, Saad Z. Usmani, Hareth Nahi, et al.
 
The authors of the abstract conclude: 
Teclistamab has a manageable safety profile across all doses explored. At the highest weekly treatment dose, a 78% overall response rate was observed in patients with advanced RRMM, supporting further evaluation of teclistamab in expansion cohorts.
 
5:38
Teclistamab for R/R myeloma
Maria-Victoria Mateos
 
 
————————————————————————————————————————————————————————
 
 
Elena Zamagni, Cristina Nanni, Francesca Gay, et al.
 
The authors of the abstract conclude: 
In conclusion, the present analysis confirms the applicability and validity of DS criteria for the definition of PET/CT MRD outside the BM in an independent prospective series of NDTEMM pts. PET/CT negativity significantly correlated with best CR. PET/CT, MFC and NGS (sensitivity of 10-5) showed a good concordance in the BM and confirmed to be complementary outside (FLs). Future analyses will show the impact of PET/CT compared to BM MRD techniques on patient’s outcomes.
 
————————————————————————————————————————————————————————
 
 
Paul G. Richardson, Annette J. Vangsted, Karthik Ramasamy, et al.
 
The authors of the abstract conclude: 
TEAEs associated with CC-92480 were related mainly to myelosuppression in heavily pretreated, including triple-class-refractory (refractory to at least one IMiD drug, one proteasome inhibitor, and one anti-CD38 antibody), patients with RRMM. Promising activity with 48% ORR at therapeutic doses was observed. The study is ongoing to further optimize the dose and schedule, with combination studies underway and dose-expansion cohorts planned.
————————————————————————————————————————————————————————
 
 
Jesus San Miguel, Nina Shah, Albert Oriol, et al.
 
The authors of the abstract conclude: 
In the KarMMa trial, ide-cel demonstrated deep, durable responses in heavily pretreated RRMM pts. Efficacy and safety results reflected prior reports and support a favorable clinical benefit-risk profile of ide-cel across the target dose levels.